148 related articles for article (PubMed ID: 21723597)
41. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Garcia AA; Sill MW; Lankes HA; Godwin AK; Mannel RS; Armstrong DK; Carolla RL; Liepman MK; Spirtos NM; Fischer EG; Leslie KK
Gynecol Oncol; 2012 Mar; 124(3):569-74. PubMed ID: 22037316
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of sorafenib in advanced thyroid cancer.
Gupta-Abramson V; Troxel AB; Nellore A; Puttaswamy K; Redlinger M; Ransone K; Mandel SJ; Flaherty KT; Loevner LA; O'Dwyer PJ; Brose MS
J Clin Oncol; 2008 Oct; 26(29):4714-9. PubMed ID: 18541894
[TBL] [Abstract][Full Text] [Related]
43. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
44. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Maki RG; D'Adamo DR; Keohan ML; Saulle M; Schuetze SM; Undevia SD; Livingston MB; Cooney MM; Hensley ML; Mita MM; Takimoto CH; Kraft AS; Elias AD; Brockstein B; Blachère NE; Edgar MA; Schwartz LH; Qin LX; Antonescu CR; Schwartz GK
J Clin Oncol; 2009 Jul; 27(19):3133-40. PubMed ID: 19451436
[TBL] [Abstract][Full Text] [Related]
46. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
Spigel DR; Hainsworth JD; Burris HA; Molthrop DC; Peacock N; Kommor M; Vazquez ER; Greco FA; Yardley DA
Clin Adv Hematol Oncol; 2011 Apr; 9(4):280-6. PubMed ID: 21558987
[TBL] [Abstract][Full Text] [Related]
47. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Schilder RJ; Brady WE; Lankes HA; Fiorica JV; Shahin MS; Zhou XC; Mannel RS; Pathak HB; Hu W; Alpaugh RK; Sood AK; Godwin AK
Gynecol Oncol; 2012 Oct; 127(1):70-4. PubMed ID: 22710075
[TBL] [Abstract][Full Text] [Related]
48. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
49. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
50. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I; Italiano A; Bompas E; Le Cesne A; Robin YM; Chevreau C; Bay JO; Bousquet G; Piperno-Neumann S; Isambert N; Lemaitre L; Fournier C; Gauthier E; Collard O; Cupissol D; Clisant S; Blay JY; Penel N;
Oncologist; 2012; 17(2):260-6. PubMed ID: 22285963
[TBL] [Abstract][Full Text] [Related]
51. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
53. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Beardsley EK; Hotte SJ; North S; Ellard SL; Winquist E; Kollmannsberger C; Mukherjee SD; Chi KN
Invest New Drugs; 2012 Aug; 30(4):1652-9. PubMed ID: 21785998
[TBL] [Abstract][Full Text] [Related]
54. Sorafenib TARGET trial results in Spanish patients.
Bellmunt J; González-Larriba JL; Climent MA; López-Vivanco G; Urruticoechea L; Albanell J
Clin Transl Oncol; 2007 Oct; 9(10):671-3. PubMed ID: 17974528
[TBL] [Abstract][Full Text] [Related]
55. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
56. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
Di Costanzo GG; Tortora R; Iodice L; Lanza AG; Lampasi F; Tartaglione MT; Picciotto FP; Mattera S; De Luca M
Dig Liver Dis; 2012 Sep; 44(9):788-92. PubMed ID: 22579445
[TBL] [Abstract][Full Text] [Related]
57. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
[TBL] [Abstract][Full Text] [Related]
58. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
59. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
60. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
